PD (Parkinson's Disease) is a neurodegenerative disease that affects millions of people worldwide. It is characterized by the loss of neurons that respond to dopamine, an essential neurotransmitter in the brain. Parkinson’s affects basic body functions, such as movement and coordination.
PD has no cure, with treatments available only able to manage and reduce symptoms. At StressMarq Biosciences, we develop alpha synuclein protein fibrils and monomers for research purposes. This protein, found in the brain and associated with the onset of PD, provides researchers with the opportunity to make headway in the search for a permanent cure for the disease.
What is Alpha-Synuclein?
This is a type of synuclein protein found in neural tissue in the brain. It’s also present in the heart, gut, and muscles, but in considerably smaller amounts. In the brain, the protein is concentrated at the tips of nerve cells in presynaptic terminals. Presynaptic terminals are responsible for the release of neurotransmitters originating from synaptic vesicles. These neurotransmitters relay signals between nerve cells in the brain, enabling normal brain function.
While the function of alpha-synuclein isn’t well understood, studies imply that this protein affects the functioning of the presynaptic terminals in relation to the neurotransmitters. They do that by limiting the mobility of synaptic vesicles.
What is the Relationship Between Parkinson’s Disease and the Alpha-Synuclein?
Parkinson's is characterized by the loss of neurotransmitters and the accumulation of protein clumps. The loss of neurotransmitters is related to the action between the synuclein protein with the synaptic vesicles.
Typically, alpha-synuclein has a wavy-like structure. However, in PD, the protein misfolds and forms an aggregate or toxic clump. The early aggregations are usually quite reactive and are believed to damage the cellular components. These aggregations also accumulate in large masses and are associated with the death of brain cells. The aggregation process of the misfolded proteins might be a trigger for Parkinson's.
When alpha-synuclein inhibits transmission within the vesicles, it restricts the action of dopamine. Dopamine plays a significant role in functions such as movement, mood, sleep, attention, learning, and blood vessel function.
Among the symptoms of PD are restless sleep, daytime sleepiness, involuntary movements, fatigue, loss of smell, anxiety, depression, difficulty speaking, and trembling. These all result from an absence of response to dopamine.
Alpha-Synuclein and Parkinson’s Disease Research
The pathological study of alpha-synuclein in connection to PD can enable discoveries that may affect the management of the condition. StressMarq Biosciences is currently developing fresh types of fibrils for the purposes of neurodegenerative disease research. Besides alpha-synuclein, our other productions include beta synuclein protein, gamma synuclein protein, SOD1, Tau, and TTR. With the alpha-synuclein fibrils and filaments, protein aggregation can be induced to bring about disease pathology in both in vitro and in vivo situations.
This gives researchers the flexibility to manipulate the proteins in a viable environment outside the human body. Besides Parkinson’s Disease, our proteins can also be used to study amyotrophic lateral sclerosis (ALS), Alzheimer’s, and amyloidosis.
Your Research Partners
At StressMarq Biosciences, we have several alpha-synuclein proteins available. These come with different primary cell activity, such as inducing alpha-synuclein phosphorylation in primary rat neurons. You can also get dopamine-stabilized alpha-synuclein oligomers from us, which is an important species connected to the occurrence of PD. Contact us today on +1 250 294-9065 for more information about alpha synuclein protein fibrils.Alpha Synuclein Protein